Terms: = Ovarian cancer AND RUNX1T1, ENSG00000079102, 862
50 results:
1. The Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer.
Nie X; Xu T; Zhang L; Cheng W
Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():97-104. PubMed ID: 38219610
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of a nomogram to predict cancer-specific survival of mucinous epithelial ovarian cancer after cytoreductive surgery.
Ma G; Zeng S; Zhao Y; Chi J; Wang L; Li Q; Wang J; Yao S; Zhou Q; Chen Y; Jiao X; Liu X; Yu Y; Huo Y; Li M; Peng Z; Ma D; Hu T; Gao Q
J Ovarian Res; 2023 Jun; 16(1):120. PubMed ID: 37370173
[TBL] [Abstract] [Full Text] [Related]
3. Concurrent Surgery for Locoregional Gynecologic cancers and Pelvic Floor Disorders in a Population of Patients With Medicare Insurance.
Corey L; Seaton R; Ruterbusch JJ; Bretschneider CE; Vezina A; Do T; Hobson D; Winer I
Obstet Gynecol; 2023 Apr; 141(4):629-641. PubMed ID: 36897144
[TBL] [Abstract] [Full Text] [Related]
4. Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response.
Chen J; Chen S; Dai X; Ma L; Chen Y; Bian W; Sun Y
Front Immunol; 2022; 13():1007326. PubMed ID: 36189254
[TBL] [Abstract] [Full Text] [Related]
5. Preoperative assessment using the five-factor modified frailty index: A call for standardized preoperative assessment and prehabilitation services in gynecologic oncology.
AlHilli MM; Schold JD; Kelley J; Tang AS; Michener CM
Gynecol Oncol; 2022 Sep; 166(3):379-388. PubMed ID: 35863992
[TBL] [Abstract] [Full Text] [Related]
6. Discriminating Between Benign and Malignant Solid ovarian Tumors Based on Clinical and Radiomic Features of MRI.
Zheng Y; Wang H; Li Q; Sun H; Guo L
Acad Radiol; 2023 May; 30(5):814-822. PubMed ID: 35810066
[TBL] [Abstract] [Full Text] [Related]
7. Tobacco Smoking and Survival Following a Diagnosis with ovarian cancer.
Wang T; Read SH; Moino D; Ayoubi Y; Chern JY; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1376-1382. PubMed ID: 35775222
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
[TBL] [Abstract] [Full Text] [Related]
9. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced ovarian/Tubal/Peritoneal cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
Copeland LJ; Brady MF; Burger RA; Rodgers WH; Huang HQ; Cella D; O'Malley DM; Street DG; Tewari KS; Bender DP; Morris RT; Lowery WJ; Miller DS; Dewdney SB; Spirtos NM; Lele SB; Guntupalli S; Ueland FR; Glaser GE; Mannel RS; DiSaia PJ
J Clin Oncol; 2022 Dec; 40(35):4119-4128. PubMed ID: 35759733
[TBL] [Abstract] [Full Text] [Related]
10. A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis.
Yang L; Yu J; Zhang S; Shan Y; Li Y; Xu L; Zhang J; Zhang J
J Ovarian Res; 2022 Feb; 15(1):26. PubMed ID: 35168642
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive Analysis of Tripterine Anti-ovarian cancer Effects Using Weighted Gene Co-Expression Network Analysis and Molecular Docking.
Long X; Liu L; Zhao Q; Xu X; Liu P; Zhang G; Lin J
Med Sci Monit; 2022 Jan; 28():e932139. PubMed ID: 35022380
[TBL] [Abstract] [Full Text] [Related]
12. Building the What Comes Next Cohort for
Dossa F; Metcalfe K; Sutradhar R; Little T; Eisen A; Chun K; Meschino WS; Velsher L; Ellis JL; Baxter NN
CMAJ Open; 2021; 9(3):E874-E885. PubMed ID: 34870614
[TBL] [Abstract] [Full Text] [Related]
13. Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO cancer Screening Trial.
Chudy-Onwugaje K; Huang WY; Su LJ; Purdue MP; Johnson CC; Wang L; Katki HA; Barry KH; Berndt SI
Cancer; 2021 Sep; 127(17):3145-3155. PubMed ID: 33974712
[TBL] [Abstract] [Full Text] [Related]
14. Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer.
Tasaka N; Minaguchi T; Hosokawa Y; Takao W; Itagaki H; Nishida K; Akiyama A; Shikama A; Ochi H; Satoh T
J Obstet Gynaecol Res; 2020 May; 46(5):765-773. PubMed ID: 32147891
[TBL] [Abstract] [Full Text] [Related]
15. Risk of Prostate cancer-related Death Following a Low PSA Level in the PLCO Trial.
Landy R; Houghton LC; Berg CD; Grubb RL; Katki HA; Black A
Cancer Prev Res (Phila); 2020 Apr; 13(4):367-376. PubMed ID: 31996370
[TBL] [Abstract] [Full Text] [Related]
16. Long non-coding RNA EPB41L4A-AS2 suppresses progression of ovarian cancer by sequestering microRNA-103a to upregulate transcription factor runx1t1.
Sun T; Yang P; Gao Y
Exp Physiol; 2020 Jan; 105(1):75-87. PubMed ID: 31645082
[TBL] [Abstract] [Full Text] [Related]
17. Current Possibilities of Gynecologic cancer Treatment with the Use of Immune Checkpoint Inhibitors.
Grywalska E; Sobstyl M; Putowski L; Roliński J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547532
[TBL] [Abstract] [Full Text] [Related]
18. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
Bick U; Engel C; Krug B; Heindel W; Fallenberg EM; Rhiem K; Maintz D; Golatta M; Speiser D; Rjosk-Dendorfer D; Lämmer-Skarke I; Dietzel F; Schäfer KWF; Leinert E; Weigel S; Sauer S; Pertschy S; Hofmockel T; Hagert-Winkler A; Kast K; Quante A; Meindl A; Kiechle M; Loeffler M; Schmutzler RK;
Breast Cancer Res Treat; 2019 May; 175(1):217-228. PubMed ID: 30725383
[TBL] [Abstract] [Full Text] [Related]
19. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract] [Full Text] [Related]
20. Model for Prediction of Optimal Debulking of Epithelial ovarian cancer.
Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
[TBL] [Abstract] [Full Text] [Related]
[Next]
